These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 20164661

  • 1. Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer.
    Chang PY, Cheng MF, Lee HS, Hsieh CB, Yao NS.
    Onkologie; 2010; 33(1-2):45-7. PubMed ID: 20164661
    [Abstract] [Full Text] [Related]

  • 2. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
    Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardière C, Boucher E, Fartoux L, Faivre S, Blanc JF, Viret F, Assenat E, Seufferlein T, Herrmann T, Grenier J, Hammel P, Dollinger M, André T, Hahn P, Heinemann V, Rousseau V, Ducreux M, Pignon JP, Wendum D, Rosmorduc O, Greten TF, BINGO investigators.
    Lancet Oncol; 2014 Jul; 15(8):819-28. PubMed ID: 24852116
    [Abstract] [Full Text] [Related]

  • 3. A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma.
    Sohal DP, Mykulowycz K, Uehara T, Teitelbaum UR, Damjanov N, Giantonio BJ, Carberry M, Wissel P, Jacobs-Small M, O'Dwyer PJ, Sepulveda A, Sun W.
    Ann Oncol; 2013 Dec; 24(12):3061-5. PubMed ID: 24146220
    [Abstract] [Full Text] [Related]

  • 4. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma.
    Guion-Dusserre JF, Lorgis V, Vincent J, Bengrine L, Ghiringhelli F.
    World J Gastroenterol; 2015 Feb 21; 21(7):2096-101. PubMed ID: 25717243
    [Abstract] [Full Text] [Related]

  • 5. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
    Leone F, Marino D, Cereda S, Filippi R, Belli C, Spadi R, Nasti G, Montano M, Amatu A, Aprile G, Cagnazzo C, Fasola G, Siena S, Ciuffreda L, Reni M, Aglietta M.
    Cancer; 2016 Feb 15; 122(4):574-81. PubMed ID: 26540314
    [Abstract] [Full Text] [Related]

  • 6. Time to move to targeted drugs in biliary tract cancer?
    Louvet C, Tournigand C.
    Onkologie; 2010 Feb 15; 33(1-2):10-1. PubMed ID: 20164655
    [No Abstract] [Full Text] [Related]

  • 7. Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma.
    Bralet MP, Bellin MF, Guettier C, Adam R, Paule B.
    Clin Oncol (R Coll Radiol); 2006 Jun 15; 18(5):426. PubMed ID: 16817335
    [No Abstract] [Full Text] [Related]

  • 8. Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.
    Knox JJ, Hedley D, Oza A, Siu LL, Pond GR, Moore MJ.
    Ann Oncol; 2004 May 15; 15(5):770-4. PubMed ID: 15111345
    [Abstract] [Full Text] [Related]

  • 9. A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202.
    Iqbal S, Rankin C, Lenz HJ, Gold PJ, Ahmad SA, El-Khoueiry AB, Messino MJ, Holcombe RF, Blanke CD.
    Cancer Chemother Pharmacol; 2011 Dec 15; 68(6):1595-602. PubMed ID: 21556747
    [Abstract] [Full Text] [Related]

  • 10. Irinotecan Plus Gemcitabine and Fluorouracil in Advanced Biliary Tract Cancer: A Retrospective Study.
    Endlicher E, Schnoy E, Troppmann M, Rogler G, Messmann H, Klebl F, Gelbmann C, Kullmann F.
    Digestion; 2016 Dec 15; 93(3):229-33. PubMed ID: 27089254
    [Abstract] [Full Text] [Related]

  • 11. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
    Pracht M, Le Roux G, Sulpice L, Mesbah H, Manfredi S, Audrain O, Boudjema K, Raoul JL, Boucher E.
    Chemotherapy; 2012 Dec 15; 58(2):134-41. PubMed ID: 22572213
    [Abstract] [Full Text] [Related]

  • 12. Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report.
    Sprinzl MF, Schimanski CC, Moehler M, Schadmand-Fischer S, Galle PR, Kanzler S.
    BMC Cancer; 2006 Jul 17; 6():190. PubMed ID: 16846514
    [Abstract] [Full Text] [Related]

  • 13. Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.
    Rubovszky G, Láng I, Ganofszky E, Horváth Z, Juhos E, Nagy T, Szabó E, Szentirmay Z, Budai B, Hitre E.
    Eur J Cancer; 2013 Dec 17; 49(18):3806-12. PubMed ID: 24007821
    [Abstract] [Full Text] [Related]

  • 14. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study.
    Iyer RV, Gibbs J, Kuvshinoff B, Fakih M, Kepner J, Soehnlein N, Lawrence D, Javle MM.
    Ann Surg Oncol; 2007 Nov 17; 14(11):3202-9. PubMed ID: 17705089
    [Abstract] [Full Text] [Related]

  • 15. Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location.
    Song BG, Park JK, Kim HS, Kim K, Park JK, Lee KH, Lee KT, Lee JK.
    Scand J Gastroenterol; 2019 Jun 17; 54(6):740-745. PubMed ID: 31136212
    [Abstract] [Full Text] [Related]

  • 16. BINGO: targeted therapy for advanced biliary-tract cancer.
    Valle JW.
    Lancet Oncol; 2014 Jul 17; 15(8):778-80. PubMed ID: 24852117
    [No Abstract] [Full Text] [Related]

  • 17. Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
    Croitoru A, Gramaticu I, Dinu I, Gheorghe L, Alexandrescu S, Buica F, Luca I, Becheanu G, Herlea V, Simionov I, Hrehoret D, Lupescu I, Popescu I, Diculescu M.
    J Gastrointestin Liver Dis; 2012 Sep 17; 21(3):277-84. PubMed ID: 23012669
    [Abstract] [Full Text] [Related]

  • 18. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.
    Raoul JL, Van Laethem JL, Peeters M, Brezault C, Husseini F, Cals L, Nippgen J, Loos AH, Rougier P.
    BMC Cancer; 2009 Apr 14; 9():112. PubMed ID: 19366444
    [Abstract] [Full Text] [Related]

  • 19. Phase II trial of combination chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced cancers of the bile duct, gallbladder, and ampulla of Vater.
    Sohn BS, Yuh YJ, Kim KH, Jeon TJ, Kim NS, Kim SR.
    Tumori; 2013 Apr 14; 99(2):139-44. PubMed ID: 23748804
    [Abstract] [Full Text] [Related]

  • 20. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
    Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ, Finch TR, Levitt R, Windschitl HE, Knost JA, Tschetter LK.
    Cancer; 2005 Jan 01; 103(1):111-8. PubMed ID: 15558814
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.